Veriheal
JANUARY 12, 2024
It demonstrates the urgent need for increased awareness and safety measures to protect workers in this evolving field. Here’s what happened and what it could mean for the future of cannabis cultivation safety. In May 2021, Lorna L. She received asthma treatment, although she had no history of the condition.
Canna Law Blog
AUGUST 28, 2022
CBD consumer safety enforcement. In March 2021, the FTC filed a complaint against Kushly Industries, LLC for making “false or unsupported claims or falsely claim that scientific evidence exists to back them up.” The post The FTC, CBD, Consumer Safety and Refunds appeared first on Harris Bricken Sliwoski LLP.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Blunt Truth
DECEMBER 9, 2021
The CBD Product Safety and Standardization Act of 2021 would mandate that the Food and Drug Administration regulate CBD as a food ingredient and establish labeling requirements and other standards. The problem is that the VA can’t prescribe medical cannabis for veterans suffering from the condition. cbd regulation.
Cannabis Law Report
SEPTEMBER 29, 2021
The Arkansas Attorney General (“AG”) issued an August 2nd Opinion addressing the scope of the safe harbor for employers provided by the Arkansas Medical Marijuana Amendment (“Amendment”) for “safety sensitive position.” Representative Wing asks whether the phrase “safety sensitive position” includes: a position. See Opinion No.
The Blunt Truth
JANUARY 5, 2022
Below are some highlights of what happened in 2021. On June 22, 2021, Connecticut legalized recreational marijuana use by adults 21 years and older. On April 12, 2021, New Mexico saw the legalization of recreational marijuana. Now is no different. Connecticut. There are numerous positions and industries exempt from the law.
Veriheal
JULY 25, 2023
The positivity rates in 2021 and 2022 were more than 30%, the highest since the all-time low in 2010-2012. in 2021 and 4.3% in 2021 and 1.5% in 2021 and 4.3% in 2021 and 1.5% in 2021 and 5.7% in 2021 and 3.9% in 2021 and 3.1% Based on the report, 7.3% The positivity for cannabis in the U.S.
Cannabis Law Report
DECEMBER 14, 2021
During the Phase 1 trial, minimal adverse events were reported, and IGC-AD1 was tolerated with no safety concerns identified by an independent Data Safety Monitoring Board. Food and Drug Administration (FDA) on December 1, 2021. Safety and Tolerability (S&T) was assessed by asking participants to record Adverse Events (AEs).
Expert insights. Personalized for you.
111 
Let's personalize your content